The short answer
Melatonin may add to lemborexant-related drowsiness and next-day impairment. Review co-use before adding it, especially when the supplement is being used as another sleep aid.
What this answer covers
Oral melatonin; dose and release formulation vary.
- Supplement or preparation
- Melatonin
- Medication ingredient
- lemborexant
Why alertness matters
Lemborexant can impair alertness and next-day activities. Its label warns about additive effects with other central nervous system depressants. That precaution does not provide an adverse-event rate for this supplement combination.
What is known about this product
Supplement-specific evidence describes drowsiness or cautions about sedative co-use. The inspected sources do not establish the risk or benefit of this exact combination.
Keep the evidence within its limits
Products differ in dose, composition and release. A study that fails to show better sleep does not prove that a product cannot impair alertness. Evidence about one extract does not establish the effects of every preparation.
Plan co-use with the prescriber
DAYVIGO labeling does not recommend use with other medicines to treat insomnia. Discuss melatonin before adding it as another sleep aid. No protective short interval is established. Avoid driving while impaired; stop DAYVIGO and contact the prescriber promptly after complex sleep behaviors.
Evidence and practical considerations
Side effects & toxicity
Conditional additive-sedation and co-use review precaution from exact medication labeling and supplement evidence. No measured pair incidence or protective timing interval; no claim of a universal botanical contraindication.
- Exact scope
- Oral melatonin; dose and release formulation vary. with Lemborexant2272403 IN, oral DAYVIGO tablets.
- Medication form and route
- oral medication; oral supplement
What remains uncertain
- No unmeasured pair incidence, blanket class transfer or arbitrary spacing interval.
Factors that may matter: Preparation; Dose; Other medicines; Organ function.
Read the supporting source summaries
Source 1: current product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: People prescribed lemborexant
Avoid strong/moderate CYP3A inhibitors and inducers; St John’s wort explicitly named. Other insomnia medicines not recommended. Additive CNS depression and complex sleep behaviors.
How this applies: Exact lemborexant RxCUI 2272403 IN, with stated salt/formulation/route bridge.
No measured seed-extract, CBD, kava or generic valerian combination risk.
Source 2: federal supplement safety guidance
nccih.nih.gov · Source check Sep 10, 2026
Population: Users of the specified supplement.
Daytime drowsiness can occur; people with epilepsy need medical supervision when using melatonin.
How this applies: Original source interpreted for lemborexant only within the stated preparation and endpoint limits.
Not a direct lemborexant combination trial; original preparation, dose and endpoint limits apply. No exact-pair adverse-event rate or protective spacing established.
Source 3: original human study
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: 16 healthy young adults.
Reaction, response and tracking performance worsened after daytime melatonin.
How this applies: Original source interpreted for lemborexant only within the stated preparation and endpoint limits.
Daytime 5 mg melatonin study in healthy volunteers; not a nighttime lemborexant combination trial or quantified pair risk.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Research summary published | |
| Article prepared | |
| Prepared exact lemborexant article with formulation-specific evidence and uncertainty. |
Article revision: 7f96c1d49191988f
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.